Avid Bioservices (CDMO) Misses Q2 EPS by 9c, adjusts guidance

December 7, 2023 4:10 PM EST

Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of ($0.15), $0.09 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $33.22 million.


Avid Bioservices sees FY2024 revenue of $137-147 million, versus the consensus of $154.1 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities